MorphoSys to Present at Six Investor Conferences

Tuesday, 03. May 2011 08:00
MorphoSys AG /
MorphoSys to Present at Six Investor Conferences
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
management will present at six investor conferences in May 2011.

Deutsche Bank's 36(th) Annual Healthcare Conference
Date:               May 2-4, 2011
Venue:             Boston, USA
Participants:   Dr. Simon Moroney, CEO of MorphoSys AG
                        Dr. Claudia Gutjahr-Löser, Head of Corporate
Communications & IR

Société Générale Corporate and Investment Banking: 6(th) Mid & Small Caps
Conference
Date:             May 5-6, 2011
Venue:          Nice, France
Participant:   Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

Deutsche Bank's German & Austrian Corporate Conference 2011
Date:             May 19-20, 2011
Venue:          Frankfurt, Germany
Participants: Dr. Simon Moroney, CEO of MorphoSys AG
                       Dr. Claudia Gutjahr-Löser, Head of Corporate
Communications & IR

BioEquity Europe
Date:             May 23-24, 2011
Venue:          Paris, France
Participant:   Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

Helvea's European Healthcare Tour 2011
Date:             May 24, 2011
Venue:          Frankfurt, Germany
Participant:   Dr. Simon Moroney, CEO of MorphoSys AG

UBS Global Specialty Pharmaceuticals Conference 2011
Date:             May 24-25, 2011
Venue:          London, UK
Participants: Dr. Simon Moroney, CEO of MorphoSys AG
                     Dr. Claudia Gutjahr-Löser, Head of Corporate Communications
& IR

The PDF versions and, if available, live and archived webcasts of company
presentations are provided at www.morphosys.com


About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys.


This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.



For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com



--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Conference Announcements May 2011:
http://hugin.info/130295/R/1511633/447050.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1511633]
Related Links: MorphoSys AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.